

Calcitonin Gene-Related Peptide CGRP Inhibitors Market Analysis 2025 – Insights for Long-Term Investment & Planning

*The Business Research Company's
Calcitonin Gene-Related Peptide CGRP
Inhibitors Global Market Report 2025 -
Market Size, Trends, And Global Forecast
2025-2034*

LONDON, GREATER LONDON, UNITED
KINGDOM, June 16, 2025

/EINPresswire.com/ -- The Business
Research Company's Latest Report

Explores Market Driver, Trends,

Regional Insights - Market Sizing & Forecasts Through 2034



The Business
Research Company

Calcitonin Gene-Related Peptide CGRP Inhibitors
Market Report 2025 - Market Size, Trends, And Global
Forecast 2025-2034

What Does The Data On The CGRP Inhibitors Market Size Indicate?

[The calcitonin gene-related peptide CGRP inhibitors market size](#) has shown significant growth in

“

The Business Research
Company's Latest Report
Explores Market Driver,
Trends, Regional Insights -
Market Sizing & Forecasts
Through 2034

”

*The Business Research
Company*

recent years. From \$2.87 billion in 2024, it is anticipated to grow to \$3.17 billion in 2025 at a compound annual growth rate CAGR of 10.6%. This growth during the historic period can partly be credited to increasing development investments, rising approval of new drugs, growing demand for non-opioid pain relievers, and an increased focus on personalized medicine.

Get Your Free Sample Market Report:

<https://www.thebusinessresearchcompany.com/sample.aspx?id=24182&type=smp>

What Is The Anticipated [Growth Of The CGRP Inhibitors Market?](#)

The CGRP inhibitors market is poised for rapid growth in the upcoming years, predicted to reach \$4.68 billion in 2029 at a CAGR of 10.2%. The acceleration in the forecast period can be attributed to the increasing prevalence of migraines, the growing adoption of preventive migraine treatments, rising patient awareness, and increasing healthcare expenditure. Trends to

watch out for during the forecast period include the advancement of technology in drug formulation, the integration of digital health tools, developments in precision medicine, and improvements in biosimilars.

what's driving the demand for CGRP inhibitors forward?

A significant factor is the increasing prevalence of migraines. These intense headaches often cause throbbing pain, usually on one side of the head, coupled with nausea, vomiting, and light and sound sensitivity. With rising levels of stress acting as a trigger, the demand for effective treatments is clear. CGRP inhibitors offer a targeted, preventative mechanism compatible with both acute and chronic care regimens, reducing headache frequency and severity through efficient CGRP receptor blockade. This improves patient well-being and daily functioning. For instance, a January 2023 report by the National Library of Medicine noted that the global prevalence of migraines is between 14% and 15%, contributing to 4.9% of the global disease burden. The growing prevalence of migraines is undeniably driving market growth.

Order Your Report Now For A Swift Delivery:

<https://www.thebusinessresearchcompany.com/report/calcitonin-gene-related-peptide-cgrp-inhibitors-global-market-report>

Who Are The Keen [Competitors In The CGRP Inhibitors Market](#)?

Leading companies such as Pfizer Inc., F. Hoffmann-La Roche AG, Merck & Co. Inc., AbbVie Inc., Bristol Myers Squibb Company, AstraZeneca plc, Novartis AG, Eli Lilly and Company, Amgen Inc., Otsuka Holdings Co. Ltd., Teva Pharmaceutical Industries Ltd., H. Lundbeck A/S, Kissei Pharmaceutical Co. Ltd., Shanghai Junshi Biosciences Co. Ltd., Shin Nippon Biomedical Laboratories Ltd., Sosei Group Corporation, Nuvie Bio Inc., Vaxxinity Inc., Acherx LLC, AfaSci Inc. are making their presence known in the CGRP inhibitors market.

What Are The Emerging Trends In The CGRP Inhibitors Market?

A trend emerging in the market is the focus on developing innovative products aimed at getting approvals, such as CGRP receptor antagonists designed to enhance migraine treatment efficacy. They offer expanded therapeutic indications and more convenient administration routes, such as oral and intranasal formulations. For instance, AbbVie Inc. received FDA approval in April 2023 for QULIPTA atogepant to treat chronic migraines in adults, cementing the drug's place in the industry.

How Is The CGRP Inhibitors Market Segmented?

The CGRP inhibitors market as covered in the report is segmented by type of inhibitor, mechanism of action, route of administration, treatment, and end user. These include:

1 By Type Of Inhibitor: Monoclonal Antibodies, Small Molecules, Peptides

2 By Mechanism Of Action: Anti-Calcitonin Gene-Related Peptide CGRP Ligand, CGRP Receptor Antagonist

3 By Route of Administration: Oral, Nasal, Intravenous

4 By Treatment: Preventive Migraine Treatment, Acute Migraine Treatment

5 By End User: Hospitals, Specialty Clinics, Mail Order Pharmacies, Retail Pharmacies

What Regional Insights Impact The CGRP Inhibitors Market Logistics?

In terms of regional insights, North America was the largest region in the CGRP inhibitors market in 2024, with Asia-Pacific projected to be the fastest-growing region.

Browse Through More Similar Reports By The Business Research Company:

Protein Inhibitors Global Market Report 2025

<https://www.thebusinessresearchcompany.com/report/protein-inhibitor-global-market-report>

Checkpoint Inhibitors Global Market Report 2025

<https://www.thebusinessresearchcompany.com/report/checkpoint-inhibitor-global-market-report>

HER2 Inhibitors Global Market Report 2025

<https://www.thebusinessresearchcompany.com/report/her2-inhibitor-global-market-report>

Get a glimpse of the market in a global perspective by the Business Research Company. With over 15000+ reports covering 27 industries and spanning 60+ geographies, the Business Research Company provides comprehensive, data-rich research and insights. Utilizing an array of 1,500,000 datasets, in-depth secondary research, and unique industry leader insights, you can stay ahead in the game.

Contact us at The Business Research Company: <https://www.thebusinessresearchcompany.com/>

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: <https://in.linkedin.com/company/the-business-research-company>

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxICpgmyFQ

Global Market Model: <https://www.thebusinessresearchcompany.com/global-market-model>

Oliver Guirdham

The Business Research Company

+44 20 7193 0708

info@tbrc.info

Visit us on social media:

[LinkedIn](#)

[Facebook](#)

[X](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/822273533>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2025 Newsmatics Inc. All Right Reserved.